GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Exicure Inc (NAS:XCUR) » Definitions » Momentum Rank

Exicure (Exicure) Momentum Rank : 2 (As of May. 14, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Exicure Momentum Rank?

Exicure has the Momentum Rank of 2.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


Competitive Comparison of Exicure's Momentum Rank

For the Biotechnology subindustry, Exicure's Momentum Rank, along with its competitors' market caps and Momentum Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Exicure's Momentum Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Exicure's Momentum Rank distribution charts can be found below:

* The bar in red indicates where Exicure's Momentum Rank falls into.



Exicure Momentum Rank Related Terms

Thank you for viewing the detailed overview of Exicure's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Exicure (Exicure) Business Description

Traded in Other Exchanges
Address
2430 N. Halsted Street, Suite 410, Chicago, IL, USA, 60614
Exicure Inc is a biotechnology company that develops nucleic acid therapies targeting ribonucleic acid against validated targets for neurological disorders and hair loss. It operates in a single segment, which is the discovery, research, and development of treatments based on its SNA (Spherical Nucleic Acid) technology.
Executives
Minhee Eom director 2430 N. HALSTED ST., CHICAGO IL 60614
Dongho Lee director 2430 N. HALSTED ST., CHICAGO IL 60614
Hyuk Joon Ko director 2430 N. HALSTED ST., CHICAGO IL 60614
Hojoon Lee director 2430 N. HALSTED ST., CHICAGO IL 60614
Dgp Co., Ltd. 10 percent owner 23, GEURINTEKEU-RO, YEONGGWANG-EUP, YEONGGWANG-GUN, JEOLLANAM-DO M5 57024
Jung Sang Kim director, officer: Chief Executive Officer, CFO 46-31 CHEONGRO 3 GIL, GEUMSUNG-MYEON, UEISUNG-GUN, GYEONGSANGBUK-DO M5 37357
Josh Miller director, officer: Chief Executive Officer, CFO 2430 N. HALSTED ST., CHICAGO IL 60614
Jiyoung Hwang director C/O EXICURE, INC., 2430 N. HALSTED ST., CHICAGO IL 60614
Cheolho Jo director 2430 N. HALSTED ST., CHICAGO IL 60614
Seung Soo Shin director 2430 N. HALSTED ST., CHICAGO IL 60614
Hyukku Lee director 2430 N. HALSTED ST., CHICAGO IL 60614
Sung Uh Kang Paul director 2430 N. HALSTED ST., CHICAGO IL 60614
Changil Ahn director 2430 N. HALSTED ST., CHICAGO IL 60614
Cbi Usa, Inc. 10 percent owner 3000 WESTERN AVENUE, SUITE 400, SEATTLE WA 98121
Bali Muralidhar director C/O EXICURE, INC., 8045 LAMON AVENUE, SUITE 410, SKOKIE IL 60077

Exicure (Exicure) Headlines

From GuruFocus

Exicure, Inc. Announces Adjournment of Annual Meeting of Stockholders

By Business Wire Business Wire 05-27-2022